| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
- 4-P-PDOT
-
- $52.00
-
2026-08-30
- CAS:134865-74-0
- Purity: 99.91%
- Supply Ability: 10g
- 4-P-PDOT
-
- $52.00
-
2026-08-20
- CAS:134865-74-0
- Purity: 99.91%
- Supply Ability: 10g
- 4-P-PDOT
-
- $1.00
-
2024-10-22
- CAS:134865-74-0
- Min. Order: 1g
- Purity: Min98%HPLC/LC
|
| | 4-P-PDOT Basic information |
| Product Name: | 4-P-PDOT | | Synonyms: | 4-PHENYL-2-PROPIONAMIDOTETRALIN;4-P-PDOT;N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide;4-P-PDOT; 4PPDOT; 4P-PDOT; AH-024; 4-PHENYL-2- PROPIONAMIDOTETRALIN.;AH-024;Propanamide, N-(1,2,3,4-tetrahydro-4-phenyl-2-naphthalenyl)-;N-(4-Phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide;Melatonin,Melatonin Receptor,GSSG,Nrf2,GSH,4PPDOT,ERK,memory,damage,Inhibitor,oxidative,4 P PDOT,MT2,inhibit | | CAS: | 134865-74-0 | | MF: | C19H21NO | | MW: | 279.38 | | EINECS: | | | Product Categories: | Melatonin receptor | | Mol File: | 134865-74-0.mol |  |
| | 4-P-PDOT Chemical Properties |
| Melting point | 166 °C | | Boiling point | 480.1±45.0 °C(Predicted) | | density | 1.11±0.1 g/cm3(Predicted) | | storage temp. | room temp | | solubility | Soluble in DMSO > 10 mM | | form | powder | | pka | 15.87±0.40(Predicted) | | color | white to beige | | InChI | 1S/C19H21NO/c1-2-19(21)20-16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,2,12-13H2,1H3,(H,20,21) | | InChIKey | RCYLUNPFECYGDW-UHFFFAOYSA-N | | SMILES | N(C1CC(c3c(cccc3)C1)c2ccccc2)C(=O)CC |
| WGK Germany | WGK 3 | | RTECS | TX1498350 | | HS Code | 2924.29.7790 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | 4-P-PDOT Usage And Synthesis |
| Uses | 4-P-PDOT is a MT2 melatonin receptor ligand. | | Definition | ChEBI: N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide is a member of tetralins. | | Biological Activity | Melatonin receptor antagonist, >300-fold selective for the MT 2 (vs MT 1 ) subtype. | | Biochem/physiol Actions | 4-P-PDOT is a slelctive MT2 melatonin receptor antagonist 300 fold selective for MT2 (MEL-1B-R) vs MT1 (MEL-1A-R) melatonin receptor subtype. | | in vivo | 4-P-PDOT (0.5-1.0 mg/kg; intravenous injection; klotho mutant mice) treatment significantly reverses antioxidant effects mediated by Melatonin. And significantly reverses the changes in the levels of these GSH-related parameters. 4-P-PDOT treatment significantly reverses the memory function of Melatonin-treated klotho mutant mice. 4-P-PDOT also counteracts Melatonin-mediated attenuation in response to the decreases in phospho-ERK expression, Nrf2 nuclear translocation, Nrf2 DNA-binding activity, and GCL mRNA expression in the hippocampi of klotho mutant mice[2]. | Animal Model: | Klotho mutant mice treatment with Melatonin[2] | | Dosage: | 0.5 mg/kg or 1.0 mg/kg | | Administration: | Intravenous injection | | Result: | Significantly reversed antioxidant effects mediated by Melatonin. Significantly reversed the changes in the levels of these GSH-related parameters. Significantly reversed the memory function of Melatonin-treated klotho mutant mice.
|
| | IC 50 | MT2 |
| | 4-P-PDOT Preparation Products And Raw materials |
|